FDA rejects alogliptin, but Takeda ‘remains confident’ (Weekend Rounds)

A review of life science current events reported by MedCity News this week: FDA rejects diabetes drug alogliptin; Takeda gives few CRL details. “We will immediately request a meeting with the FD…
Read the full story: MedCity News